Published in Blood on July 21, 2005
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
In vivo two-photon imaging reveals monocyte-dependent neutrophil extravasation during pulmonary inflammation. Proc Natl Acad Sci U S A (2010) 2.54
Acute graft-versus-host disease: from the bench to the bedside. Blood (2009) 2.24
Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol (2010) 1.51
CCL2 blockade augments cancer immunotherapy. Cancer Res (2009) 1.48
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant (2010) 1.38
PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest (2009) 1.37
NOD2 regulates hematopoietic cell function during graft-versus-host disease. J Exp Med (2009) 1.30
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol (2008) 1.24
Acute graft-versus-host disease: a bench-to-bedside update. Blood (2014) 1.23
CCR2 regulates monocyte recruitment as well as CD4 T1 allorecognition after lung transplantation. Am J Transplant (2010) 1.17
The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. J Clin Invest (2009) 1.11
Involvement of Hofbauer cells and maternal T cells in villitis of unknown aetiology. Histopathology (2008) 1.11
CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood (2008) 1.08
Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst (2010) 0.98
Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI. Blood (2008) 0.96
Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. Blood (2013) 0.96
Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood (2007) 0.92
Organ-derived dendritic cells have differential effects on alloreactive T cells. Blood (2008) 0.90
Donor and recipient chemokine receptor CCR5 genotype is associated with survival after bone marrow transplantation. Blood (2010) 0.87
Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood (2008) 0.87
Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease. Expert Opin Pharmacother (2008) 0.87
Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease. J Immunol (2010) 0.86
Shift of graft-versus-host-disease target organ tropism by dietary vitamin A. PLoS One (2012) 0.83
Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation. Korean J Intern Med (2009) 0.81
The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics. Front Pharmacol (2012) 0.79
Lithothamnion muelleri controls inflammatory responses, target organ injury and lethality associated with graft-versus-host disease in mice. Mar Drugs (2013) 0.79
PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Cancer Res (2013) 0.78
Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses. Cancer Res (2016) 0.77
Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. Biol Blood Marrow Transplant (2014) 0.76
Nanocomposite treatment reduces disease and lethality in a murine model of acute graft-versus-host disease and preserves anti-tumor effects. PLoS One (2015) 0.75
Allogeneic splenocyte transfer and lipopolysaccharide inhalations induce differential T cell expansion and lung injury: a novel model of pulmonary graft-versus-host disease. PLoS One (2014) 0.75
Silencing CCR2 in Macrophages Alleviates Adipose Tissue Inflammation and the Associated Metabolic Syndrome in Dietary Obese Mice. Mol Ther Nucleic Acids (2016) 0.75
Role of C-C motif ligand 2 and C-C motif receptor 2 in murine pulmonary graft-versus-host disease after lipopolysaccharide inhalations. Am J Respir Cell Mol Biol (2014) 0.75
Dynamics of M1 macrophages in oral mucosal lesions during the development of acute graft-versus-host disease in rats. Clin Exp Immunol (2017) 0.75
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (1998) 8.92
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 8.56
Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest (1997) 7.58
Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A (1994) 6.65
T-cell function and migration. Two sides of the same coin. N Engl J Med (2000) 6.47
Chemokines and disease. Nat Immunol (2001) 5.62
Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci U S A (1997) 5.54
Graft-versus-host disease. N Engl J Med (1991) 5.35
Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol (2004) 5.07
An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood (1996) 4.65
Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med (1997) 4.57
Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood (1997) 4.51
Chemokines as regulators of T cell differentiation. Nat Immunol (2001) 3.37
Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med (2000) 3.15
Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol (2001) 3.13
CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med (2000) 3.09
A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging (2004) 3.07
Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol (2002) 2.92
Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol (2003) 2.90
Haematopoietic cell transplantation as immunotherapy. Nature (2001) 2.88
Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2001) 2.59
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood (2001) 2.45
Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest (2001) 2.39
Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol (2001) 2.38
Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today (1996) 2.21
Leukocyte migration and graft-versus-host disease. Blood (2005) 2.17
An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med (1997) 2.10
Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J Exp Med (1999) 2.09
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol (1993) 1.98
A mechanism for the impaired IFN-gamma production in C-C chemokine receptor 2 (CCR2) knockout mice: role of CCR2 in linking the innate and adaptive immune responses. J Immunol (2000) 1.92
Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest (1999) 1.91
The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med (1996) 1.72
LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood (2003) 1.67
CCR2-dependent trafficking of F4/80dim macrophages and CD11cdim/intermediate dendritic cells is crucial for T cell recruitment to lungs infected with Mycobacterium tuberculosis. J Immunol (2004) 1.67
Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity. J Immunol (2002) 1.59
IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest (2003) 1.56
Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J Immunol (2004) 1.50
Chemokine receptor 2 (CCR2) in atherosclerosis, infectious diseases, and regulation of T-cell polarization. Microcirculation (2003) 1.48
Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol (2002) 1.48
Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood (2001) 1.46
Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol (2003) 1.46
IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest (1999) 1.44
Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol (2002) 1.32
Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays. Blood (2003) 1.30
Lack of CCR2 results in increased mortality and impaired leukocyte activation and trafficking following infection of the central nervous system with a neurotropic coronavirus. J Immunol (2001) 1.27
Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease. J Invest Dermatol (1986) 1.24
The current status of hematopoietic cell transplantation. Annu Rev Med (2001) 1.20
CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood (2005) 1.19
Ccr2 regulates the level of MCP-1/CCL2 in vitro and at inflammatory sites and controls T cell activation in response to alloantigen. Cytokine (2002) 1.18
Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest (2003) 1.16
T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant (2002) 1.08
Kinetics of gene expression in murine cutaneous graft-versus-host disease. Am J Pathol (2004) 1.08
Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells. Blood (2000) 1.06
A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood (2003) 1.03
CCR2: from cloning to the creation of knockout mice. Chem Immunol (1999) 1.01
FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol (2004) 0.98
CC chemokine receptor 2 expression in donor cells serves an essential role in graft-versus-host-disease. J Immunol (2003) 0.94
Differential expression of chemokines and chemokine receptors in murine islet allografts: the role of CCR2 and CCR5 signaling pathways. J Am Soc Nephrol (2004) 0.91
Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2005) 0.90
Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. Transplantation (2004) 0.84
2-Mercaptoimidazoles, a new class of potent CCR2 antagonists. Bioorg Med Chem Lett (2005) 0.83
Post-BMT lung injury occurs independently of the expression of CCL2 or its receptor, CCR2, on host cells. Am J Physiol Lung Cell Mol Physiol (2003) 0.81
The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells. J Immunol (1986) 0.80
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Identification of cells initiating human melanomas. Nature (2008) 8.28
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011) 7.49
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst (2009) 5.05
Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest (2010) 4.95
Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med (2006) 4.71
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med (2002) 3.94
Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation (2011) 3.81
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 3.17
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med (2007) 3.07
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest (2012) 3.00
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
Interleukin-22 drives endogenous thymic regeneration in mice. Science (2012) 2.96
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (2007) 2.92
Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood (2010) 2.73
Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis (2012) 2.72
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol (2008) 2.68
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood (2011) 2.68
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol (2011) 2.45
Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res (2005) 2.44
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A (2004) 2.41
Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology (2003) 2.35
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol (2012) 2.26
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest (2008) 2.23
Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood (2008) 2.21
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol (2007) 2.12
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest (2005) 2.10
IL-17 contributes to CD4-mediated graft-versus-host disease. Blood (2008) 2.07
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol (2006) 1.99
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res (2005) 1.97
Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood (2011) 1.97
Sentinel lymph nodes in a swine model with melanoma: contrast-enhanced lymphatic US. Radiology (2004) 1.95
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol (2004) 1.91
Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J Allergy Clin Immunol (2009) 1.91
Identification of liver cancer-specific aptamers using whole live cells. Anal Chem (2008) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med (2005) 1.88
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol (2003) 1.87
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl (2006) 1.86
A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol (2006) 1.86
Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. Nat Med (2013) 1.86
Intestinal microbiota containing Barnesiella species cures vancomycin-resistant Enterococcus faecium colonization. Infect Immun (2013) 1.85
Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med (2006) 1.85
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res (2010) 1.84
Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant (2010) 1.83
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol (2013) 1.83
The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res (2007) 1.83
Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood (2012) 1.81
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res (2007) 1.80
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med (2011) 1.78
Nature's TRAIL--on a path to cancer immunotherapy. Immunity (2003) 1.77
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology (2003) 1.76
A "no-wash" albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions. Biol Blood Marrow Transplant (2009) 1.76
Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology (2007) 1.75
Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab (2006) 1.74
Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood (2011) 1.72
Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol (2005) 1.72
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol (2008) 1.71
T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant (2011) 1.71
Cyclooxygenase-2 and Akt mediate multiple growth-factor-induced epithelial-mesenchymal transition in human hepatocellular carcinoma. J Gastroenterol Hepatol (2012) 1.70
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood (2003) 1.67
Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med (2008) 1.67
Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood (2009) 1.67
Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration. Blood (2005) 1.65